Market News

Essex Investment Management Co Has Decreased Its Celgene (CELG) Stake by $557,815; Shares Declined; As Kohl’s (KSS) Share Value Declined, Shareholder Laffer Investments Has Trimmed Its Position

Laffer Investments decreased its stake in Kohl’s Corp (KSS) by 6.86% based on its latest 2017Q3 regulatory filing with the SEC. Laffer Investments sold 1,970 shares as the company’s stock declined 10.79% while stock markets rallied. The institutional investor held 26,752 shares of the department and specialty retail stores company at the end of 2017Q3, valued at $1.22 billion, down from 28,722 at the end of the previous reported quarter. Laffer Investments who had been investing in Kohl’s Corp for a number of months, seems to be less bullish one the $10.73B market cap company. The stock increased 4.50% or $2.75 during the last trading session, reaching $63.87. About 7.48M shares traded or 65.13% up from the average. Kohl's Corporation (NYSE:KSS) has risen 7.16% since January 14, 2017 and is uptrending. It has underperformed by 9.54% the S&P500.

Essex Investment Management Co Llc decreased its stake in Celgene Corp (CELG) by 3.21% based on its latest 2017Q3 regulatory filing with the SEC. Essex Investment Management Co Llc sold 3,847 shares as the company’s stock declined 3.49% while stock markets rallied. The hedge fund held 116,134 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $16.94M, down from 119,981 at the end of the previous reported quarter. Essex Investment Management Co Llc who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $83.46 billion market cap company. The stock increased 1.36% or $1.42 during the last trading session, reaching $106. About 8.75M shares traded or 5.20% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 14, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Laffer Investments, which manages about $614.32 million and $378.86B US Long portfolio, upped its stake in Arconinc (Rti) by 1 shares to 1,053 shares, valued at $1.19B in 2017Q3, according to the filing. It also increased its holding in Stanley Black & Decker by 1,045 shares in the quarter, for a total of 28,360 shares, and has risen its stake in Ishares 1 (CSJ).

Analysts await Kohl's Corporation (NYSE:KSS) to report earnings on February, 22. They expect $1.45 EPS, up 0.69% or $0.01 from last year’s $1.44 per share. KSS’s profit will be $243.60 million for 11.01 P/E if the $1.45 EPS becomes a reality. After $0.70 actual EPS reported by Kohl's Corporation for the previous quarter, Wall Street now forecasts 107.14% EPS growth.

Investors sentiment increased to 0.94 in Q3 2017. Its up 0.08, from 0.86 in 2017Q2. It is positive, as 46 investors sold KSS shares while 169 reduced holdings. 73 funds opened positions while 129 raised stakes. 175.28 million shares or 0.56% less from 176.27 million shares in 2017Q2 were reported. Wilsey Asset Mngmt stated it has 5.05% of its portfolio in Kohl's Corporation (NYSE:KSS). Advantus Cap holds 0.02% or 16,798 shares in its portfolio. Moreover, Aviva Public Ltd Com has 0.03% invested in Kohl's Corporation (NYSE:KSS) for 105,923 shares. 289,264 were reported by Federated Investors Pa. 5,026 are owned by Oppenheimer Asset Mngmt. Chevy Chase accumulated 147,399 shares. Thompson has 105,259 shares. Washington Tru Comml Bank has 1,000 shares. 655,584 are owned by Cwm Ltd Co. Twin Capital accumulated 47,078 shares. Meeder Asset Mgmt Inc, a Ohio-based fund reported 21,962 shares. Gulf Bank (Uk) Ltd holds 0.04% or 60,262 shares in its portfolio. Hartford Investment Mngmt Com stated it has 0.03% in Kohl's Corporation (NYSE:KSS). 223,181 were accumulated by Denver Advsr. Moreover, Tower Research Limited Liability (Trc) has 0% invested in Kohl's Corporation (NYSE:KSS) for 100 shares.

Among 27 analysts covering Kohl’s Corporation (NYSE:KSS), 11 have Buy rating, 2 Sell and 14 Hold. Therefore 41% are positive. Kohl’s Corporation had 90 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, November 10 by M Partners. The firm has “Buy” rating given on Monday, December 18 by Jefferies. Citigroup upgraded Kohl's Corporation (NYSE:KSS) on Monday, November 14 to “Buy” rating. M Partners downgraded the shares of KSS in report on Thursday, February 4 to “Neutral” rating. The firm earned “Neutral” rating on Friday, February 10 by Susquehanna. Telsey Advisory maintained the shares of KSS in report on Tuesday, January 9 with “Buy” rating. The rating was maintained by Telsey Advisory Group with “Outperform” on Friday, November 11. The stock of Kohl's Corporation (NYSE:KSS) earned “Neutral” rating by Northcoast on Friday, December 8. The rating was maintained by Telsey Advisory Group with “Outperform” on Friday, May 13. The stock has “Hold” rating by Gordon Haskett on Thursday, August 10.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 EPS, up 24.11% or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38B for 15.14 P/E if the $1.75 EPS becomes a reality. After $1.78 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69% negative EPS growth.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation had 124 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Argus Research given on Monday, July 31. The firm has “Buy” rating given on Sunday, October 15 by Jefferies. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, October 5 by BMO Capital Markets. The stock of Celgene Corporation (NASDAQ:CELG) earned “Outperform” rating by Oppenheimer on Monday, October 30. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, July 27. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Friday, October 27 by SunTrust. Stifel Nicolaus maintained Celgene Corporation (NASDAQ:CELG) on Thursday, September 7 with “Buy” rating. The rating was maintained by Morgan Stanley on Monday, October 23 with “Underweight”. BTIG Research downgraded the stock to “Neutral” rating in Wednesday, June 1 report. The firm earned “Buy” rating on Friday, November 6 by Canaccord Genuity.

Essex Investment Management Co Llc, which manages about $740.27 million and $735.81 million US Long portfolio, upped its stake in Harvard Bioscience Inc (NASDAQ:HBIO) by 111,359 shares to 540,819 shares, valued at $2.03M in 2017Q3, according to the filing. It also increased its holding in Electromed Inc (NYSEMKT:ELMD) by 44,931 shares in the quarter, for a total of 74,885 shares, and has risen its stake in Gilead Sciences Inc (NASDAQ:GILD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *